By John L. LaMattina
An expert's view on fixing the demanding situations confronting latest pharmaceutical industry
Author John LaMattina, a thirty-year veteran of the pharmaceutical and previous president of Pfizer's worldwide R&D department, is across the world well-known as knowledgeable at the pharmaceutical undefined. His first e-book, Drug Truths: Dispelling the Myths approximately Pharma R&D, used to be seriously acclaimed for clearing up misconceptions concerning the pharmaceutical and delivering a good account of the contributions of pharmaceutical study and improvement to human overall healthiness and well-being.
As he toured the rustic discussing Drug Truths, Dr. LaMattina on a regular basis came upon those that have been choked with anger, accusing the pharmaceutical of constructing up illnesses, hiding risky unintended effects, and extra. This e-book was once written according to that have, severely reading public perceptions and realities.
Starting with "4 secrets and techniques that Drug businesses don't desire You to Know," Devalued and Distrusted presents a fact-based account of ways the pharmaceutical works and the demanding situations it faces. It addresses such severe matters as:
- Why pharmaceutical R&D productiveness has declined
- Where pharmaceutical businesses have to make investments their resources
- What should be performed to unravel center health and wellbeing demanding situations, together with melanoma, diabetes, and neurodegenerative diseases
- How the pharmaceutical can regain public belief and resuscitate its image
Our knowing of human overall healthiness and ailment grows day-by-day; in spite of the fact that, changing technological know-how into drugs is more and more difficult. interpreting Devalued and Distrusted, you are going to not just achieve a better appreciation of these demanding situations, but in addition the function that the pharmaceutical at present performs and will play in fixing these challenges.
Get to understand the writer: Read an interview with John LaMattina or watch a video on ChemistryViews!
Chapter 1 The 4 secrets and techniques the Drug businesses don't need You to grasp (pages 4–24):
Chapter 2 What has occurred to R&D productiveness? (pages 25–48):
Chapter three Key healing parts for bettering well-being (pages 49–70):
Chapter four enhancing R&D Output (pages 71–95):
Chapter five Restoring Pharma's photo (pages 96–108):
Chapter 6 ultimate concepts (pages 109–114):
Read or Download Devalued and Distrusted: Can the Pharmaceutical Industry Restore its Broken Image? PDF
Similar pharmacology books
In 1943, Albert Schatz, a tender Rutgers collage Ph. D. scholar, labored on a wartime venture in microbiology professor Selman Waksman’s lab, trying to find an antibiotic to struggle infections at the entrance traces and at domestic. In his 11th scan on a typical bacterium present in farmyard soil, Schatz found streptomycin, the 1st powerful medication for tuberculosis, one of many world’s deadliest ailments.
As director of Schatz’s study, Waksman took credits for the invention, belittled Schatz’s paintings, and secretly enriched himself with royalties from the streptomycin patent filed by way of the pharmaceutical corporation Merck. In an extraordinary lawsuit, younger Schatz sued Waksman, and was once offered the identify of “co-discoverer” and a proportion of the royalties. yet years later, Professor Waksman by myself was once presented the Nobel Prize. Schatz disappeared into educational obscurity.
For the 1st time, acclaimed writer and journalist Peter Pringle unravels the intrigues at the back of some of the most very important discoveries within the heritage of drugs. the tale unfolds on a tiny collage campus in New Jersey, yet its repercussions unfold around the globe. The streptomycin patent used to be a leap forward for the drug businesses, overturning patent limits on items of nature and paving the best way for today’s biotech international. As dozens extra antibiotics have been came upon, many from a similar kinfolk as streptomycin, the drug businesses created oligopolies and reaped substantial earnings. Pringle makes use of firsthand debts and records within the usa and Europe to bare the intensely human tale in the back of the invention that all started a revolution within the therapy of infectious illnesses and formed the way forward for large Pharma.
The research of G-quadruplexes has emerged in recent times as a tremendous concentration of study in nucleic acids. this can be now a swiftly transforming into sector, no longer least as a result of its strength as a unique method of melanoma therapeutics, and there's a lot present task at the layout of quadruplex-selective small-molecule ligands and the learn in their mobile results.
This definitive resource ebook on psychoactive medicinal drugs . . . presents user-friendly discussions of every substance's nature, the way it is probably going to impact the physique, and what precautions are essential to restrict any capability for damage. largely illustrated with images and line drawings.
- WHO Expert Committee on Specifications for Pharmaceutical Preparations (40th report)
- Glutathione - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References
- Hallucinogens, Neurochemical, Behavioral, and Clinical Perspectives
- New Approaches to Drug Discovery
- Epigenetic targets in drug discovery
Additional resources for Devalued and Distrusted: Can the Pharmaceutical Industry Restore its Broken Image?
12 If size is detrimental to an innovative research culture, mergers between large companies should make things worse—and they do. They have a strong negative personal impact on researchers and, consequently, the innovative research environment. For example, the merger of Bristol Myers with Squibb in 1989, which I witnessed, was a scene of power grabs and disintegrating morale. Researchers who could get a good offer left the company, and the positions of those who remained were often decided by favouritism rather than talent.
7 These two trends may be related. Smaller biotech companies and particularly start-up companies look to Big Pharma for support of new drug programs, especially as they enter more expensive clinical trials. As Big Pharma R&D budgets shrink, there is less money to invest both internally and externally. Thus, over the past 15 years, private sector R&D has been shrinking predominately in researchers but more recently in dollars invested. This is now occurring across the entire R&D health-care sector.
As a result, no venture capital firm will now finance a new effort to develop a drug for the obesity epidemic. Freund is not alone in these views. The CEO of the French pharmaceutical company Sanofi, Chris Viehbacher, echoed these same sentiments. 19 His concern is that companies cannot predict how the FDA will weigh the risk–benefit for drugs to treat diabetes and obesity. The result is that companies are shying away from R&D in this area. In reading this, one would think that the FDA is way too conservative in evaluating drugs, particularly in treating chronic diseases like obesity and diabetes that affect millions of Americans.